Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), retaining the price target of $105.00. Michael Ulz has given his Buy rating
Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), retaining the price target of $105.00. Michael Ulz has given his Buy rating
Following “disappointing results” from competitors’ oral obesity drugs, Oppenheimer analyst Jay Olson tells investors that the firm views the black box warning assigned to GLP1 drugs as “a hangover from
Bullish option flow detected in Viking Therapeutics with 31,237 calls trading, 5x expected, and implied vol increasing almost 5 points to 77.04%. Sep-24 70 calls and Oct-24 90 calls are
Unusual total active option classes on open include: Vanguard Total Bond (BND), Nasdaq 100 Micro Index (.XND), ALTC Acquisition Corp (OKLO), Nike (NKE), Nuscale Power Corp (SMR), Vistra Energy (VST),
In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $95.00. The company’s shares